Pancreatic Cancer Research

ResearcherFred Hutch Cancer CenterActive in the last 2 years

Sudhir Srivastava

ORCID-verified (high confidence, 0.95), identity_conf@1As of 6 November 2026

Matched on ORCID iD 0000-0002-7798-9772; OpenAlex author ID A5101623259. Sources: OpenAlex.

Their work

Papers
21 (first author 1, last author 2)
Trials
0
Grants
0
Labs led
1
Collaborators
120
Papers, trials and grants by year

2015: 3 papers · 2016: 3 papers · 2017: 1 paper · 2018: 6 papers · 2019: none · 2020: 1 paper · 2021: 3 papers · 2022: 1 paper · 2023: none · 2024: 2 papers · 2025: none · 2026: 1 paper

Papers 21

  1. Pancreatic Cancer Detection Consortium Biomarker Bakeoff: A Phase II Blinded Biomarker Validation and Panel Discovery Study. Co-author DOI 10.1158/1078-0432.ccr-25-4061↗
  2. Clinical development of a blood biomarker using apolipoprotein-A2 isoforms for early detection of pancreatic cancer. Co-author DOI 10.1007/s00535-023-02072-w↗
  3. Early detection of pancreatic cancer: Study design and analytical considerations in biomarker discovery and early phase validation studies. Co-author DOI 10.1016/j.pan.2024.10.012↗
  4. Early Detection Initiative: A randomized controlled trial of algorithm-based screening in patients with new onset hyperglycemia and diabetes for early detectio… Co-author DOI 10.1016/j.cct.2021.106659↗
  5. The national institutes of health's approach to address research gaps in pancreatitis, diabetes and early detection of pancreatic cancer. Co-author DOI 10.1097/mog.0000000000000758↗
  6. Artificial Intelligence and Early Detection of Pancreatic Cancer: 2020 Summative Review. Co-author DOI 10.1097/mpa.0000000000001762↗
  7. Early Detection of Pancreatic Cancer: Applying Artificial Intelligence to Electronic Health Records. Co-author DOI 10.1097/mpa.0000000000001882↗
  8. Prediagnostic Image Data, Artificial Intelligence, and Pancreatic Cancer: A Tell-Tale Sign to Early Detection. Last author DOI 10.1097/mpa.0000000000001603↗
  9. Validation of Biomarkers for Early Detection of Pancreatic Cancer: Summary of The Alliance of Pancreatic Cancer Consortia for Biomarkers for Early Detection Wo… Last author DOI 10.1097/mpa.0000000000000973↗
  10. Consortium for the Study of Chronic Pancreatitis, Diabetes, and Pancreatic Cancer: From Concept to Reality. Co-author DOI 10.1097/mpa.0000000000001167↗
  11. Evaluation of a Mixed Meal Test for Diagnosis and Characterization of PancrEaTogEniC DiabeTes Secondary to Pancreatic Cancer and Chronic Pancreatitis: Rational… Co-author DOI 10.1097/mpa.0000000000001168↗
  12. A Prospective Study to Establish a New-Onset Diabetes Cohort: From the Consortium for the Study of Chronic Pancreatitis, Diabetes, and Pancreatic Cancer. Co-author DOI 10.1097/mpa.0000000000001169↗
  13. PROspective Evaluation of Chronic Pancreatitis for EpidEmiologic and Translational StuDies: Rationale and Study Design for PROCEED From the Consortium for the … Co-author DOI 10.1097/mpa.0000000000001170↗
  14. Standard Operating Procedures for Biospecimen Collection, Processing, and Storage: From the Consortium for the Study of Chronic Pancreatitis, Diabetes, and Pan… Co-author DOI 10.1097/mpa.0000000000001171↗
  15. A Plasma Biomarker Panel to Identify Surgically Resectable Early-Stage Pancreatic Cancer. Co-author DOI 10.1093/jnci/djw341↗
  16. Early Detection of Pancreatic Cancer-a Defined Future Using Lessons From Other Cancers: A White Paper. Co-author DOI 10.1097/mpa.0000000000000701↗
  17. Pancreatic Cancer Chemoprevention Translational Workshop: Meeting Report. Co-author DOI 10.1097/mpa.0000000000000705↗
  18. Potential usefulness of apolipoprotein A2 isoforms for screening and risk stratification of pancreatic cancer. First author DOI 10.2217/bmm-2016-0209↗
  19. Plasma biomarker for detection of early stage pancreatic cancer and risk factors for pancreatic malignancy using antibodies for apolipoprotein-AII isoforms. Co-author DOI 10.1038/srep15921↗
  20. Early detection of sporadic pancreatic cancer: summative review. Co-author DOI 10.1097/mpa.0000000000000368↗
  21. Definitive Characterization of CA 19-9 in Resectable Pancreatic Cancer Using a Reference Set of Serum and Plasma Specimens. Co-author DOI 10.1371/journal.pone.0139049↗

Closest collaborators

The 25 strongest of 120 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Jo Ann Rinaudo · 12 shared papers, 2015–2022 · strength 0.98
  2. Suresh T. Chari · 8 shared papers, 2015–2022 · strength 0.62
  3. Brian Matthew Wolpin · 4 shared papers, 2016–2026 · strength 0.52
  4. Michael Goggins · 4 shared papers, 2016–2026 · strength 0.52
  5. José Serrano · 6 shared papers, 2018–2021 · strength 0.50
  6. Kenneth S. Zaret · 3 shared papers, 2018–2026 · strength 0.47
  7. Barbara J. Kenner · 5 shared papers, 2015–2022 · strength 0.45
  8. Suyu Liu · 3 shared papers, 2017–2026 · strength 0.45
  9. Dana K. Andersen · 5 shared papers, 2015–2021 · strength 0.43
  10. Ying Huang · 5 shared papers, 2015–2024 · strength 0.43
  11. Ziding Feng · 5 shared papers, 2018–2022 · strength 0.42
  12. Anirban Maitra · 5 shared papers, 2015–2022 · strength 0.39
  13. Lynette M. Smith · 2 shared papers, 2024–2026 · strength 0.39
  14. Ann L. Oberg · 2 shared papers, 2024–2026 · strength 0.39
  15. Shounak Majumder · 2 shared papers, 2024–2026 · strength 0.39
  16. Randall E. Brand · 5 shared papers, 2015–2024 · strength 0.37
  17. Stephen Jacob Pandol · 5 shared papers, 2018–2021 · strength 0.36
  18. Matthew R. Young · 3 shared papers, 2018–2021 · strength 0.34
  19. Subrata Sen · 3 shared papers, 2015–2026 · strength 0.32
  20. Seetharaman Balasenthil · 3 shared papers, 2015–2026 · strength 0.32
  21. Ann McNeill Killary · 3 shared papers, 2015–2026 · strength 0.32
  22. Kazufumi Honda · 3 shared papers, 2015–2024 · strength 0.31
  23. Vay Liang W. Go · 4 shared papers, 2015–2021 · strength 0.31
  24. Michael Anthony Hollingsworth · 3 shared papers, 2015–2026 · strength 0.30
  25. Ann E. Goldberg · 3 shared papers, 2016–2021 · strength 0.27

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.